Mubadala Bio has finalised the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) from Yas Holding’s GlobalOne Healthcare Holding. The transaction follows an initial 80 percent stake acquired at the end of 2024.
Moreover, the completion of the deal marks further progress in building a vertically integrated life sciences platform in the UAE. By aligning biopharmaceutical manufacturing with pharmaceutical logistics under a unified strategy, the company aims to enhance coordination and operational efficiency. Therefore, the acquisition strengthens its ability to deliver critical healthcare products across the country.
Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, said: “This strategic move supports Mubadala Bio’s vertical integration strategy, creating greater efficiency and stronger coordination across the life sciences value chain. It also reinforces national drug security by ensuring essential healthcare products are consistently available across the UAE.”
Low Ping, Group CEO of Yas Holding, commented, “The proven capability and reach of both companies will help ensure resilience and efficiency not just across Mubadala Bio’s growing life sciences platform, but also our national healthcare supply chain.”
Through full ownership of IDS and GMSC, Mubadala Bio advances national drug security objectives. Additionally, it reinforces pharmaceutical distribution networks and supports the UAE’s ambition to build a resilient, innovation-driven healthcare ecosystem.
